Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actavis announced that it has launched a generic version of Intuniv (guanfacine hydrochloride), as part of a settlement agreement with Shire.
Subscribe to our email newsletter
Actavis has begun shipping the product and, under applicable Hatch Waxman rules, is entitled to 180 days of marketing exclusivity.
Intuniv is a prescription medicine used to treat Attention Deficit Hyperactivity Disorder in patients ages 6 to 17. For the 12-month period ending June 30, 2014, Intuniv had U.S. sales of approximately $668 million, according to IMS Health data.
Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories.
The company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.